These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1188321)

  • 1. Transient impaired cell-mediated tumor immunity after acute infection with lymphocytic choriomeningitis virus.
    Güttler F; Bro-Jorgensen K; Jorgensen PN
    Scand J Immunol; 1975; 4(4):327-36. PubMed ID: 1188321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional heterogeneity of lymphocytic choriomeningitis virus-specfic T lymphocytes. I. Identification of effector amd memory subsets.
    Johnson ED; Cole GA
    J Exp Med; 1975 Apr; 141(4):866-81. PubMed ID: 47887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection.
    Moskophidis D; Assmann-Wischer U; Simon MM; Lehmann-Grube F
    Eur J Immunol; 1987 Jul; 17(7):937-42. PubMed ID: 2886344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.
    Zinkernagel RM; Doherty PC
    Nature; 1974 Apr; 248(5450):701-2. PubMed ID: 4133807
    [No Abstract]   [Full Text] [Related]  

  • 5. T lymphocyte function as the principal target of lymphocytic choriomeningitis virus-induced immunosuppression.
    Bro-Jorgensen K; Güttler F; Jorgensen PN; Volkert M
    Infect Immun; 1975 Apr; 11(4):622-9. PubMed ID: 235488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers.
    Gilden DH; Cole GA; Nathanson N
    J Exp Med; 1972 Apr; 135(4):874-89. PubMed ID: 4622913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twp populations of T lymphocytes immune to the lymphocytic choriomeningitis virus.
    Volkert M; Marker O; Bro-Jorgensen K
    J Exp Med; 1974 May; 139(5):1329-43. PubMed ID: 4545164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interplay between target organ concentrations of lymphocytic choriomeningitis virus and cell mediated immunity in baby mice.
    Marker O; Thorner Andersen G; Volkert M
    Acta Pathol Microbiol Scand C; 1976 Feb; 84(1):23-30. PubMed ID: 1266623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;
    Zinkernagel RM; Doherty PC
    J Exp Med; 1975 Jun; 141(6):1427-36. PubMed ID: 47901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The timing of the immune response in relation to virus growth determines the outcome of the LCM infection.
    Thomsen AR; Volkert M; Marker O
    Acta Pathol Microbiol Scand C; 1979 Feb; 87C(1):47-54. PubMed ID: 433605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immune reactivity to hepatoma 22a cells in MTV-infected compared with MTV-free C3H mice.
    Lavrovsky VA; Viksler VK
    Immunology; 1981 Dec; 44(4):671-6. PubMed ID: 6274791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological tolerance to lymphocytic choriomeningitis virus in neonatally infected virus carrier mice: evidence supporting a clonal inactivation mechanism.
    Cihak J; Lehmann-Grube F
    Immunology; 1978 Feb; 34(2):265-75. PubMed ID: 304840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 14. The immune response of the mouse to lymphocytic choriomeningitis virus. II. Active suppression of cell-mediated immunity by infection with high virus doses.
    Lehmann-Grube F; Cihak J; Varho M; Tijerina R
    J Gen Virol; 1982 Feb; 58(Pt 2):223-35. PubMed ID: 6460847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal macrophages as target cells for measuring virus-specific T cell mediated cytotoxicity in vitro.
    Zinkernagel RM; Doherty PC
    J Immunol Methods; 1975 Sep; 8(3):263-6. PubMed ID: 52680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incompatibility at irrelevant H-2 specificities augments in vivo stimulation of alloaggressive cells.
    Jorgensen PN
    Scand J Immunol; 1975; 4(4):373-82. PubMed ID: 52889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of the interaction in vitro between cytotoxic thymus-derived lymphocytes and target monolayers infected with lymphocytic choriomeningitis virus.
    Zinkernagel RM; Doherty PC
    Scand J Immunol; 1974; 3(3):287-94. PubMed ID: 4546752
    [No Abstract]   [Full Text] [Related]  

  • 18. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo growth and antigenic properties of a rat sarcoma induced by Moloney sarcoma virus.
    Jones JM; Jensen F; Veit B; Feldman JD
    J Natl Cancer Inst; 1974 Jun; 52(6):1771-7. PubMed ID: 4134500
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas.
    Leclerc JC; Gomard E; Levy JP
    Int J Cancer; 1972 Nov; 10(3):589-601. PubMed ID: 4128690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.